These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 17272827)

  • 41. Use of FLIPR membrane potential dyes for validation of high-throughput screening with the FLIPR and microARCS technologies: identification of ion channel modulators acting on the GABA(A) receptor.
    Joesch C; Guevarra E; Parel SP; Bergner A; Zbinden P; Konrad D; Albrecht H
    J Biomol Screen; 2008 Mar; 13(3):218-28. PubMed ID: 18270364
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of assay technologies for a nuclear receptor assay screen reveals differences in the sets of identified functional antagonists.
    Wu X; Glickman JF; Bowen BR; Sills MA
    J Biomol Screen; 2003 Aug; 8(4):381-92. PubMed ID: 14567790
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Deconvolution of combinatorial libraries for Drug discovery: theoretical comparison of pooling strategies.
    Konings DA; Wyatt JR; Ecker DJ; Freier SM
    J Med Chem; 1996 Jul; 39(14):2710-9. PubMed ID: 8709101
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Statistical and graphical methods for quality control determination of high-throughput screening data.
    Gunter B; Brideau C; Pikounis B; Liaw A
    J Biomol Screen; 2003 Dec; 8(6):624-33. PubMed ID: 14711388
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Designing screens: how to make your hits a hit.
    Walters WP; Namchuk M
    Nat Rev Drug Discov; 2003 Apr; 2(4):259-66. PubMed ID: 12669025
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PowerMV: a software environment for molecular viewing, descriptor generation, data analysis and hit evaluation.
    Liu K; Feng J; Young SS
    J Chem Inf Model; 2005; 45(2):515-22. PubMed ID: 15807517
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The discovery of Kv1.5 blockers as a case study for the application of virtual screening approaches.
    Pirard B; Brendel J; Peukert S
    J Chem Inf Model; 2005; 45(2):477-85. PubMed ID: 15807513
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Multiplex GPCR assay in reverse transfection cell microarrays.
    Mishina YM; Wilson CJ; Bruett L; Smith JJ; Stoop-Myer C; Jong S; Amaral LP; Pedersen R; Lyman SK; Myer VE; Kreider BL; Thompson CM
    J Biomol Screen; 2004 Apr; 9(3):196-207. PubMed ID: 15140381
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Plate-based diversity selection based on empirical HTS data to enhance the number of hits and their chemical diversity.
    Sukuru SC; Jenkins JL; Beckwith RE; Scheiber J; Bender A; Mikhailov D; Davies JW; Glick M
    J Biomol Screen; 2009 Jul; 14(6):690-9. PubMed ID: 19531667
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Using the protein chip to screen agonists and antagonists of the androgen receptor.
    Zhou Y; Liu A; Wang W; Du G
    J Biomol Screen; 2008 Apr; 13(4):276-84. PubMed ID: 18349422
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Virtual screening - what does it give us?
    Köppen H
    Curr Opin Drug Discov Devel; 2009 May; 12(3):397-407. PubMed ID: 19396741
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of SPA, FRET, and FP for kinase assays.
    Wu JJ
    Methods Mol Biol; 2002; 190():65-85. PubMed ID: 12029827
    [No Abstract]   [Full Text] [Related]  

  • 53. Simulation modeling of pooling for combinatorial protein engineering.
    Polizzi KM; Spencer CU; Dubey A; Matsumura I; Lee JH; Realff MJ; Bommarius AS
    J Biomol Screen; 2005 Dec; 10(8):856-64. PubMed ID: 16234344
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Statistical evaluation of a self-deconvoluting matrix strategy for high-throughput screening of the CXCR3 receptor.
    Ferrand S; Schmid A; Engeloch C; Glickman JF
    Assay Drug Dev Technol; 2005 Aug; 3(4):413-24. PubMed ID: 16180996
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Scintillation proximity assays in high-throughput screening.
    Glickman JF; Schmid A; Ferrand S
    Assay Drug Dev Technol; 2008 Jun; 6(3):433-55. PubMed ID: 18593378
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A cost-effective solution to reduce dead volume of a standard dispenser system by a factor of 5.
    Bergsdorf C; Gewiese N; Stolz A; Mann R; Parczyk K; Bömer U
    J Biomol Screen; 2006 Jun; 11(4):407-12. PubMed ID: 16490776
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A simple strategy for mitigating the effect of data variability on the identification of active chemotypes from high-throughput screening data.
    Johnson SR; Padmanabha R; Vaccaro W; Hermsmeier M; Cacace A; Lawrence M; Dickey J; Esposito K; Pike K; Wong V; Poss M; Loughney D; Tebben A
    J Biomol Screen; 2007 Mar; 12(2):276-84. PubMed ID: 17272827
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High-throughput determination of mode of inhibition in lead identification and optimization.
    Wei M; Wynn R; Hollis G; Liao B; Margulis A; Reid BG; Klabe R; Liu PC; Becker-Pasha M; Rupar M; Burn TC; McCall DE; Li Y
    J Biomol Screen; 2007 Mar; 12(2):220-8. PubMed ID: 17351185
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Practical approaches to efficient screening: information-rich screening protocol.
    Karnachi PS; Brown FK
    J Biomol Screen; 2004 Dec; 9(8):678-86. PubMed ID: 15634794
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reading dynamic kinase activity in living cells for high-throughput screening.
    Allen MD; DiPilato LM; Rahdar M; Ren YR; Chong C; Liu JO; Zhang J
    ACS Chem Biol; 2006 Jul; 1(6):371-6. PubMed ID: 17163774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.